Walleye Trading’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,200
Closed -$330K 4791
2025
Q4
$330K Buy
+1,200
New +$328K ﹤0.01% 3091
2025
Q3
Sell
-4,400
Closed -$963K 4882
2025
Q2
$963K Buy
4,400
+3,500
+389% +$748K ﹤0.01% 2225
2025
Q1
$201K Sell
900
-1,900
-68% -$524K ﹤0.01% 3081
2024
Q4
$917K Buy
2,800
+2,500
+833% +$787K ﹤0.01% 2224
2024
Q3
$90K Buy
+300
New +$91.9K ﹤0.01% 3349
2024
Q2
Sell
-300
Closed -$119K 5001
2024
Q1
$119K Sell
300
-700
-70% -$259K ﹤0.01% 3695
2023
Q4
$352K Sell
1,000
-3,700
-79% -$1.31M ﹤0.01% 3377
2023
Q3
$1.76M Buy
4,700
+4,300
+1,075% +$1.66M ﹤0.01% 1882
2023
Q2
$153K Sell
400
-200
-33% -$71.4K ﹤0.01% 3565
2023
Q1
$208K Buy
+600
New +$175K ﹤0.01% 3481
2022
Q2
Sell
-200
Closed -$82K 5749
2022
Q1
$82K Sell
200
-100
-33% -$39.1K ﹤0.01% 4342
2021
Q4
$141K Sell
300
-800
-73% -$344K ﹤0.01% 4178
2021
Q3
$467K Buy
1,100
+100
+10% +$42.2K ﹤0.01% 2984
2021
Q2
$359K Buy
+1,000
New +$330K ﹤0.01% 3307
2018
Q3
Sell
-2,100
Closed -$209K 5591
2018
Q2
$209K Buy
+2,100
New +$193K ﹤0.01% 3612

Other funds holding WST

Walleye Trading's WST Position: Q1 2026 in Review

Walleye Trading sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 663 shares — an estimated $182K sold.

Walleye Trading first reported a position in WST in Q3 2016 and held it in 12 quarters. The position peaked at $1.77M in Q2 2025. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Walleye Trading reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 663 West Pharmaceutical shares in Q1 2026, an estimated $182K.
  • Walleye Trading first reported a position in West Pharmaceutical in Q3 2016 and held it in 12 quarters.
  • Walleye Trading's West Pharmaceutical position peaked at $1.77M in Q2 2025.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.